论文部分内容阅读
[目的]观察羟考酮缓释片在多西他赛二线治疗伴随疼痛的晚期肺癌患者的疗效及安全性。[方法]对2007年2月—2011年7月收治的40例中、重度肿瘤疼痛者采用羟考酮缓释片止痛,同时予多西他赛75 mg/m2静脉滴注1 h,第1天,每3周重复。观察治疗前后疗效、不良反应及生活质量评分。[结果]有效率27.5%,疾病控制率60%,中位生存期9.35个月,1年生存率37.5%。与治疗前比较,患者疼痛程度有较大的缓解,疼痛缓解率为97.5%,数字模拟评分法(NRS)评分明显降低,KPS评分明显升高,差异均具有统计学意义(P<0.05)。不良反应主要是血液学毒性和便秘,治疗后可以缓解。[结论]羟考酮缓释片联合多西他赛治疗中重度疼痛的肺癌安全有效,能明显改善病人的生活质量。
[Objective] To observe the efficacy and safety of oxycodone sustained-release tablets in the second-line docetaxel treatment of advanced lung cancer patients with pain. [Methods] Oxycodone sustained-release tablets were used in 40 patients with moderate-to-severe tumor pain who were treated from February 2007 to July 2011. The patients were treated with docetaxel 75 mg / Day, repeated every 3 weeks. Observed before and after treatment efficacy, adverse reactions and quality of life scores. [Results] The effective rate was 27.5%, the disease control rate was 60%, the median survival time was 9.35 months and the 1-year survival rate was 37.5%. The pain relief rate was 97.5%. Compared with the pretreatment, the NRS score was significantly lower and the KPS score was significantly higher. The difference was statistically significant (P <0.05). Adverse reactions are mainly hematologic toxicities and constipation, which can be relieved after treatment. [Conclusion] oxycodone extended-release tablets combined with docetaxel in the treatment of moderate-severe lung cancer is safe and effective, which can significantly improve the quality of life of the patients.